Alfuzosin Once Daily Facilitates Return to Voiding in Patients in Acute Urinary Retention

Abstract

Alfuzosin (10 mg) once daily significantly improved the rate of successful TWOC in patients with AUR related to BPH, even in elderly patients and those with a large drained volume who were at increased risk for TWOC failure. This should contribute to decrease the morbidity and mortality associated with emergency surgery and avoid the discomfort and potential morbidity associated with an in situ catheter.

Urinary retention presenting as complete bowel obstruction

“…TWOC can be attempted, although if hydronephrosis or renal impairment is present the patient should remain with indwelling catheter until surgery. 7 Although our patient had over 1000 mL of residual urine, which is a factor leading to a high probability of unsuccessful TWOC, 10 we still decided to pursue TWOC because he was under 65 years old and had good detrusor function. In patients with low-pressure, chronic urinary retention prostatectomy is in many cases unsuccessful as they fail to void completely after surgery and require long-term or clean intermittent self-catheterization.…”

1098 Efficacy and safety of silodosin and dutasteride combination therapy in acute urinary retention due to benign prostatic hyperplasia: A single-arm prospective study

“…The successful voiding rate was significantly higher in patients treated with alfuzosin than in those treated with placebo (62% versus 48%, resp. ; = 0.002) [7]. Various clinical trials have demonstrated that ABs, including tamsulosin and alfuzosin, are effective and safe in AUR management, with successful removal percentages that range from 48% to 70% [15].…”

“…The large randomized, double-blind, placebo-controlled alfuzosin in another AUR study investigated the impact of AB on the outcome of TWOC [7]. Three hundred sixty patients with a first episode of AUR-related BPH were randomized to receive 10 mg alfuzosin once daily or placebo for 2-3 days following catheterization [7]. The successful voiding rate was significantly higher in patients treated with alfuzosin than in those treated with placebo (62% versus 48%, resp.…”

“…Currently, TWOC after AB therapy is also the recommended treatment option for patients with AUR. The large randomized, double-blind, placebo-controlled alfuzosin in another AUR study investigated the impact of AB on the outcome of TWOC [7]. Three hundred sixty patients with a first episode of AUR-related BPH were randomized to receive 10 mg alfuzosin once daily or placebo for 2-3 days following catheterization [7].…”

“…Although a trial without catheter (TWOC) is the standard of care for AUR [5], TWOC typically involves removing the catheter after 3 days, which allows only 23%-40% of patients to void successfully [5,6]. TWOC in which catheter removal followed 2-3 days of -blocker (AB) improves success rates [7]. Kumar et al reported that silodosin significantly increased the chances of successful TWOC after AUR [8].…”